mRNA Past, Present, and Future

Update: 2023-08-17

Description

Chris Spivey, editorial director, hosts a wide ranging discussion on the COVID-19 pandemic response, future government communications, and healthcare funding for mRNA with experts Dr. Kate Broderick, Chief Innovation Officer, Maravai LifeSciences and Dr. Tom Madden, President & CEO at Acuitas Therapeutics.

Comments

In Channel

Innovations in Orphan Drugs for Rare Diseases

2025-11-2611:35

Sustainable Solutions for Biopharma

2025-07-3110:34

Novel Drug Delivery Approaches: Refining AAV Vector Deliveries

2025-05-3012:15

Equipment Trends for Addressing Production of New Modalities

2025-03-2216:05

Forecasting Pharma’s Future

2025-01-2818:02

Realizing AI’s Potential

2024-12-1818:38

Dosage Forms: Roundtable On Oral Solid Dosage Trends

2024-10-3020:01

Alternative Drug Delivery Methods for Biologics: Where Are We At?

2024-09-2616:20

Meeting Industry Needs: Fill/Finish Advances from a CDMO Perspective

2024-09-1024:28

Growth and Advancements in Fill/Finish

2024-06-2519:19

All About Data: Looking at the EHDS in More Detail

2024-05-2813:14

A Closer Look at mRNA in Oncology and Vaccines

2024-04-3024:12

Applying Appropriate Analytics to Drug Development

2024-03-2624:07

The Biosimilars Landscape

2024-01-3127:58

Staying on Track with Formulation of Cell Culture Media

2023-12-0524:47

Gliding Through the Ins and Outs of the Pharma Supply Chain

2023-11-1421:35

Digital Transformation in the Biopharma Industry

2023-10-1924:07

Starting Up in the CGT Manufacturing Space

2023-10-0525:38

Breaking Through the Barriers of Drug Development

2023-09-0520:27

mRNA Past, Present, and Future

2023-08-1730:37

00:00

mRNA Past, Present, and Future

#box-pro-ellipsis-176670229583677{-webkit-line-clamp:2;}mRNA Past, Present, and Future

mRNA Past, Present, and Future

Pharm Tech

mRNA Past, Present, and Future